CSP #512 - Options in Management With Anti-Retrovirals (OPTIMA)
CSP #512 - Options in Management With Anti-Retrovirals (OPTIMA), Management of Patients With HIV Infection for Whom First and Second-line Highly Active Anti-Retroviral Therapy Has Failed
Sponsor: Canadian Institutes of Health Research (CIHR)
A NA clinical study on AIDS and HIV Infections, this trial is completed. The trial is conducted by Canadian Institutes of Health Research (CIHR) and has accumulated 9 data snapshots since 2001. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2023 — Jul 2024 [monthly]
Completed NA
-
Dec 2022 — Jan 2023 [monthly]
Completed NA
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed NA
-
Aug 2018 — Jan 2021 [monthly]
Completed NA
-
Jun 2018 — Aug 2018 [monthly]
Completed NA
-
Jan 2017 — Jun 2018 [monthly]
Completed NA
First recorded
Jan 2001
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Canadian Institutes of Health Research (CIHR)
- Medical Research Council
- US Department of Veterans Affairs
For direct contact, visit the study record on ClinicalTrials.gov .